The compounds OPB-31121, OPB-51602 and OPB-111077, which are substances from Otsuka Pharmaceuticals, were designed to inhibit STAT3 phosphorylation in cancer cell lines and xenograft models by targeting the STAT3 SH2 domain. The gene discussed is STAT3; the disease is cancer.